My name is Maxim Izergin. I'm 48 years old, I live in Oslo, Norway, and I've been fighting multiple myeloma — an incurable blood cancer — for 15 years.

I have two sons. Markus is 19 and just starting his adult life. Martin is 11 and still needs his dad at every fencing competition, every homework struggle, every bedtime conversation. They are the reason I fight.

I was first diagnosed in 2011. Since then, I've gone through every treatment the Norwegian healthcare system could offer — multiple lines of chemotherapy, a stem cell transplant in 2023, and countless hospital stays. Each time, I fought back. Each time, I returned to my family, to my work, to life.

In March 2026, the cancer returned aggressively. My tumor markers doubled in six weeks. MRI scans showed new lesions spreading through my spine and pelvis. My doctors started emergency bridging chemotherapy to buy time — but time for what?

There is a therapy that could save my life: CAR-T cell therapy (Carvykti). It's a revolutionary one-time treatment where my own immune cells are re-engineered to hunt and destroy cancer cells. It has shown remarkable results in multiple myeloma patients — long-term remissions where other treatments have failed.

CAR-T therapy is approved and funded in Sweden, Denmark, Germany, Spain, the UK, and many other European countries. But not in Norway.

Norway's drug reimbursement committee (Beslutningsforum) has rejected Carvykti twice — in May 2024 and again in March 2026 — citing cost concerns. Meanwhile, the same committee approved an alternative chronic treatment (Blenrep) that costs roughly €880,000 over its expected treatment period — more than double the cost of a single CAR-T infusion. The difference? Blenrep requires hospital visits every three weeks, indefinitely, and causes significant eye toxicity in most patients. CAR-T is given once.

Norway's leading myeloma specialist told me directly: "You cannot join the clinical study — it means no treatment until May, and that's too long for you." The other major hospital confirmed no manufacturing slot is available for approximately two months. My cancer is not waiting.

I am a taxpayer. I run two technology companies — INFOSS and AI Factory — employing people and contributing over 2 million NOK annually in personal and business taxes. I've paid into this system my entire adult life. And now, when I need it most, the system cannot help me.

After contacting over 20 hospitals across Europe, I have been accepted for CAR-T therapy at Charité — Universitätsmedizin Berlin, one of Europe's most respected university hospitals. They have reviewed my medical records, prepared an official treatment plan, and are ready to begin as soon as payment is received.

The treatment cost is €367,700. This is the lowest quote I received from any hospital in Europe — roughly half of what UK hospitals quoted.

What the Money Covers

Total goal €450,000

The treatment process takes several months: cell collection (leukapheresis), 4–6 weeks of cell manufacturing, conditioning chemotherapy, CAR-T infusion, and a critical monitoring period. My wife and I will need to stay in Berlin throughout.

Every week matters. My M-protein levels — a direct measure of cancer activity — went from 9 to 16 to 23 g/L in just six weeks. I am currently on bridging chemotherapy to slow the disease, but this is a temporary measure. The sooner we begin the CAR-T process, the better my chances of a successful outcome.

Charité is ready. The treatment plan is signed. All that stands between me and this therapy is the funding.

Any contribution — large or small — brings me closer to treatment. If you cannot donate, sharing this campaign is just as powerful. One share can reach someone who can help.

I have never asked for help like this before. I've always been the one working, building, solving problems. But this is a problem I cannot solve alone.

I want to see Martin grow up. I want to be there when Markus builds his future. I want more years with my family.

Please help me get there.

All medical records, hospital correspondence, and the official Charité cost estimate are available for verification. I am committed to full transparency — any funds not used for treatment will be returned to donors or donated to myeloma research.